{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:46:58Z","timestamp":1793774818467,"version":"4.6.1"},"reference-count":36,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,5,15]]},"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct pathophysiological mechanisms, clinical features and treatment responses. Rituximab is a licensed therapy for granulomatosis with polyangiitis and microscopic polyangiitis but there is limited experience of rituximab in EGPA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>EGPA patients from a tertiary centre who received rituximab for mostly refractory EGPA or in whom cyclophosphamide was contra indicated were studied. A standardised dataset was collected at time of initial treatment and every 3 months for 24 months. Response was defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 and partial response as \u226550% reduction in BVAS from baseline. Remission was defined as a BVAS of 0 on prednisolone dose \u22645 mg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-nine patients (44 female) received rituximab between 2003 and 2017. Improvement (response and partial response) was observed in 76.8% of patients at 6 months, 82.8% at 12 months and in 93.2% by 24 months, while relapses occurred in 54% by 24 months, with asthma being the most frequent manifestation. The median BVAS decreased from 6 at baseline to 1 at 6 months, and 0 at 12 and 24 months. Prednisolone dose (mg\/day, median) decreased from 12.5 to 7, 7.5 and 5 at 6, 12 and 24 months, respectively. ANCA positive patients had a longer asthma\/ear, nose and throat (ENT) relapse-free survival time and a shorter time to remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Rituximab demonstrated some efficacy in EGPA and led to a reduction in prednisolone requirement, but asthma and ENT relapse rates were high despite continued treatment. The ANCA positive subset appeared to have a more sustained response on isolated asthma\/ENT exacerbations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-000905","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T07:15:34Z","timestamp":1559805334000},"page":"e000905","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":92,"title":["Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9452-0028","authenticated-orcid":false,"given":"V\u00edtor","family":"Teixeira","sequence":"first","affiliation":[{"name":"Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK"},{"name":"Servi\u00e7o de Reumatologia e Doen\u00e7as \u00d3sseas Metab\u00f3licas, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio de Lisboa Norte, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aladdin J","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK"},{"name":"Clinical Sciences, Rheumatology, Lund University, Lund, Sk\u00e5ne, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B","family":"Jones","sequence":"additional","affiliation":[{"name":"Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Smith","sequence":"additional","affiliation":[{"name":"Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[{"name":"Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"2025090312483612000_5.1.e000905.1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.40375","article-title":"Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised international chapel Hill consensus Conference Nomenclature of vasculitides","volume":"70","author":"Sunderk\u00f6tter","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312483612000_5.1.e000905.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21250"},{"key":"2025090312483612000_5.1.e000905.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-267542"},{"key":"2025090312483612000_5.1.e000905.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes171"},{"key":"2025090312483612000_5.1.e000905.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.27678"},{"key":"2025090312483612000_5.1.e000905.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209133"},{"key":"2025090312483612000_5.1.e000905.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079"},{"key":"2025090312483612000_5.1.e000905.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.22679"},{"key":"2025090312483612000_5.1.e000905.9","first-page":"176","article-title":"Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial","volume":"35 Suppl 103","author":"Samson","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312483612000_5.1.e000905.10","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Pu\u00e9chal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312483612000_5.1.e000905.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169"},{"key":"2025090312483612000_5.1.e000905.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"2025090312483612000_5.1.e000905.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404231"},{"key":"2025090312483612000_5.1.e000905.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken175"},{"key":"2025090312483612000_5.1.e000905.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.155382"},{"key":"2025090312483612000_5.1.e000905.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206605"},{"key":"2025090312483612000_5.1.e000905.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo","year":"2017","journal-title":"PLoS One"},{"key":"2025090312483612000_5.1.e000905.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206095"},{"key":"2025090312483612000_5.1.e000905.19","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","article-title":"Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis","volume":"5","author":"Thiel","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025090312483612000_5.1.e000905.20","first-page":"31","article-title":"Development and validation of a disease extent index for Wegener's granulomatosis","volume":"55","author":"de Groot","year":"2001","journal-title":"Clin Nephrol"},{"key":"2025090312483612000_5.1.e000905.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279"},{"key":"2025090312483612000_5.1.e000905.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062711"},{"key":"2025090312483612000_5.1.e000905.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.24637"},{"key":"2025090312483612000_5.1.e000905.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213277"},{"key":"2025090312483612000_5.1.e000905.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.37721"},{"key":"2025090312483612000_5.1.e000905.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket257"},{"key":"2025090312483612000_5.1.e000905.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.34583"},{"key":"2025090312483612000_5.1.e000905.28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/acr.22686","article-title":"Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"68","author":"Durel","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025090312483612000_5.1.e000905.29","first-page":"118","article-title":"[Churg-Strauss syndrome: outcome and long-term follow-up of 38 patients from a single Italian centre]","volume":"61","author":"Baldini","year":"2009","journal-title":"Reumatismo"},{"key":"2025090312483612000_5.1.e000905.30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-9-200511010-00006"},{"key":"2025090312483612000_5.1.e000905.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.04.022"},{"key":"2025090312483612000_5.1.e000905.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.03.002"},{"key":"2025090312483612000_5.1.e000905.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.015453"},{"key":"2025090312483612000_5.1.e000905.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160907"},{"key":"2025090312483612000_5.1.e000905.35","doi-asserted-by":"crossref","unstructured":"Lyons P , Peters J , Alberici F , et al . Genetically distinct clinical subsets, and associations with asthma and eosinophil abundance, within eosinophilic granulomatosis with polyangiitis. bioRxiv 2018.","DOI":"10.1101\/491837"},{"key":"2025090312483612000_5.1.e000905.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211897"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-000905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:48:43Z","timestamp":1756928923000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,6,5]]},"published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1136\/rmdopen-2019-000905"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-000905","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}